Given that TP53 is a tumor suppressor gene and variation in TP53 and is a predictive marker for immunotherapy in HNSCC (16) it is reasonable to hypothesize that if feline immune checkpoint drugs were available their use in the rapidly growing FOSCC could be efficacious. The gene discussed is TP53; the disease is head and neck squamous cell carcinoma.